Robert L. (Bob) Obenchain is a biostatistician and pharmaco-epidemiologist specializing in observational comparative effectiveness research, heterogeneous treatment effects (personalized/individual...ver maisRobert L. (Bob) Obenchain is a biostatistician and pharmaco-epidemiologist specializing in observational comparative effectiveness research, heterogeneous treatment effects (personalized/individualized medicine) and risk assessment-mitigation strategies for marketed pharmaceutical products. He is currently the Principal Consultant for Risk Benefit Statistics, LLC, in Indianapolis, IN. Bob received his BS in Engineering-Science from Northwestern and his PhD in Mathematical Statistics from UNC-Chapel Hill. Bob spent 16 years in research at AT&T Bell Labs, followed by an associate director role in non-clinical statistics at GlaxoSmithKline, before spending 17 years at Eli Lilly as a Sr. Research Advisor and Group Leader of statistical consulting in Health Outcomes Research.
Bob was elected as a Fellow of American Statistical Association (ASA) in 1997. He has also served on a variety of statistical methodological roles for SAMSI, NISS, and FNIH, and as an adjunct Professor of Biostatistics at the University of North Carolina and the Indiana University Medical School.ver menos